semaglutide bupropion & Tirzepatide Compounded GLP-1 (Semaglutide) - bmiMD
Description
We monitor your progress closely to make precise adjustments
The companys revenue has skyrocketed since it began selling compounded GLP-1s, from $271.9 million in 2021 to $1.5 billion in 2024
Weight management is a long-term endeavour, and medication is most effective when combined with sustained lifestyle changes
Patients with kidney disease, cardiovascular disease, liver conditions, or a history of eating disorders should avoid highly restrictive diets unless supervised medically
Microdosing uses lower doses
Other GLP-1 RAs were not included because many of these agents are older, less effective at weight reduction and therefore not reflective of contemporary treatment of excess body weight
